

ANGIODYNAMICS INC

Reported by
CAMPBELL CHAD THOMAS

FORM 4

(Statement of Changes in Beneficial Ownership)

Filed 07/18/25 for the Period Ending 07/16/25

Address	14 PLAZA DRIVE LATHAM, NY, 12110
Telephone	5187981215
CIK	0001275187
Symbol	ANGO
SIC Code	3841 - Surgical and Medical Instruments and Apparatus
Industry	Medical Equipment, Supplies & Distribution
Sector	Healthcare
Fiscal Year	05/31

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden hours per response... 0.5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or
Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *	2. Issuer Name and Ticker or Trading Symbol	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
Campbell Chad Thomas	ANGIODYNAMICS INC [ANGO]	Director 10% Owner
(Last) (First) (Middle)	3. Date of Earliest Transaction (MM/DD/YYYY)	X Officer (give title below) Other (specify below)
14 PLAZA DRIVE	7/16/2025	SVP/GM, Vascular Access
(Street)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line)
LATHAM, NY 12110		X Form filed by One Reporting Person
(City) (State) (Zip)		Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code V	Amount (A) or (D) Price			
Common Stock	7/16/2025		A	26,268 (1) A \$0	94,076	D	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code V	(A) (D)	Date Exercisable Expiration Date	Title Amount or Number of Shares				
Performance Right	(2)	7/16/2025		A	26,268	(2) (2)	Common Stock 26,268	\$0	26,268	D	

Explanation of Responses:

- (1) The acquisition of 26,268 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 26,268 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 16, 2026, such that 25% of the restricted stock units will vest on each of July 16, 2026, 2027, 2028 and 2029.
- (2) Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

Remarks:
Exhibit 24.1 - Power of Attorney

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director 10% Owner Officer Other
Campbell Chad Thomas	

SUBSTITUTE POWER OF ATTORNEY

Pursuant to the terms of certain Powers of Attorney (the “Powers of Attorney”), the undersigned, Stephen A. Trowbridge, was appointed a true and lawful attorney-in-fact, with full power of substitution, to do and perform every act and thing whatsoever requisite, necessary or proper to be done in the exercise of the rights and powers granted in such Powers of Attorney, by certain officers and directors of AngioDynamics, Inc. (the “Company”), including Chad Campbell (the “PoA Party”).

Additionally, the Powers of Attorney ratified and confirmed all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, lawfully do or cause to be done by virtue of the Powers of Attorney and the rights and powers granted therein.

In accordance with the authority granted under the Powers of Attorney, including the power of substitution, the undersigned hereby appoints Lawrence T. Weiss as a substitute attorney-in-fact, on behalf of the PoA Party, to exercise and execute all of the powers granted or conferred in the applicable Power of Attorney. By his signature as an attorney-in-fact to this Substitute Power of Attorney, Lawrence T. Weiss accepts such appointment and agrees to assume from the undersigned any and all duties and responsibilities attendant to his capacity as an attorney-in-fact. This Substitute Power of Attorney supersedes any and all prior Substitute Powers of Attorney whereby Stephen A. Trowbridge appointed any individual as a substitute attorney-in-fact on behalf of the PoA Party under the authority granted under the Powers of Attorney. This Substitute Power of Attorney shall remain in full force and effect until the earlier of (i) such time as this Substitute Power of Attorney is revoked by the undersigned, Stephen A. Trowbridge, or by the PoA Party, (ii) such time as this Substitute Power of Attorney is superseded by a new substitute power of attorney regarding the purposes outlined herein dated as of a later date, or (iii) such time as the PoA Party is no longer required to file Forms 3, 4, and 5 with respect to such PoA Party’s holdings of and transactions in securities issued by the Company.

[Signature Page Follows]

IN WITNESS WHEREOF, the undersigned has executed this Substitute Power of Attorney this 20th day of January, 2025.

By:

/s/ Stephen A. Trowbridge

Stephen A. Trowbridge
Attorney-in-Fact

I accept this appointment and substitution:

/s/ Lawrence T. Weiss

Lawrence T. Weiss
